Every pharmaceutical importer and distributor faces the same operational challenge: finding a single, reliable source that covers the breadth of their market’s medicine requirements without forcing them to juggle ten different suppliers, ten different documentation chains, and ten different delivery timelines.
At Afif Overseas Pvt. Ltd., we built our export model specifically to solve that problem. Based in Ahmedabad, Gujarat, we connect importers and distributors across the Middle East, Africa, and Asia with a wide, certified, and consistently available pharmaceutical product portfolio sourced from India’s best manufacturing facilities.
This blog gives you a clear picture of what we export, why each therapeutic category matters for your market, and how working with a single experienced Indian exporter simplifies your procurement without limiting your range.
India manufactures over 60,000 generic brands across 60 therapeutic categories. Anti-infectives led the Indian pharmaceutical market with a 34 percent share in 2025, while oncology is growing at the fastest rate, projected at a CAGR of 8.22 percent through 2031. Whatever your market needs most right now, India is already producing it at scale.
Anti-Infectives and Antibiotics: The Highest Volume, the Highest Demand
For most importers in the Middle East and Africa, antibiotics and anti-infective medicines form the single largest category of pharmaceutical procurement. This reflects real healthcare realities on the ground. Drug-resistant infections are increasing globally, viral outbreaks remain a persistent challenge, and access to effective broad-spectrum antibiotics is directly tied to patient survival outcomes.
India is the world’s leading supplier of anti-infective APIs and formulations. Our portfolio includes broad-spectrum antibiotics across oral and injectable formats, antifungals, antivirals including antiretrovirals, and anti-parasitic medicines. For markets with high procurement volumes in this category, we offer scalable supply with full WHO-GMP documentation.
Cardiovascular Medicines: Serving a Growing Chronic Disease Burden
Cardiovascular disease is the leading cause of death globally and the burden in emerging markets is rising sharply. For distributors supplying hospitals and private pharmacies, the demand for antihypertensives, statins, anticoagulants, and heart failure therapies is not seasonal. It is continuous, predictable, and growing year on year.
Our cardiovascular range covers the core molecules that appear in most national formularies and procurement tender lists. These include ACE inhibitors, beta-blockers, calcium channel blockers, antiplatelet agents, and combination tablets for patients managing multiple risk factors. All products come with batch-specific CoAs and stability data.
Diabetes Management: One of the Fastest-Growing Segments Globally
The global diabetes epidemic is well-documented, and markets across the MENA region and Sub-Saharan Africa are experiencing some of the sharpest increases in prevalence. For importers, this translates into sustained long-term demand for antidiabetic medicines across both the public and private sectors.
Our diabetes range includes oral antidiabetics such as metformin and combination tablets, as well as insulin formulations for markets with hospital and outpatient insulin programmes. As the generic antidiabetic market continues to expand with new molecule exclusivity expiries, we stay current with the pipeline so your procurement options grow alongside your market needs.
Oncology: Affordable Generics for a Specialty That Cannot Wait
Oncology has historically been one of the most expensive segments of pharmaceutical procurement. Branded cancer drugs carry price tags that place them out of reach for most patients in developing and emerging markets. Generic oncology medicines from India are changing that reality.
India’s oncology API and formulation capabilities have expanded rapidly in recent years. Over 60 complex, high-revenue oncology molecules are now being manufactured generically by Indian producers. Our oncology portfolio includes cytotoxics, hormone therapies, targeted therapy generics, and supportive care medicines used alongside chemotherapy. For importers supplying specialty hospitals or oncology centres, we provide complete dossiers and can support Ministry of Health registration processes.
The Indian API market is projected to grow from USD 14.8 billion in 2025 to USD 22 billion by 2030, with oncology and anti-infectives driving the fastest growth. Importers who build oncology supply relationships with certified Indian exporters now are positioning themselves ahead of the demand curve.
Respiratory, Gastroenterology, and CNS: The Everyday Essentials
Beyond the headline therapeutic areas, the day-to-day volume of pharmaceutical procurement is driven by medicines for respiratory conditions, digestive disorders, and neurological care. Our portfolio in these areas is extensive:
- Respiratory: bronchodilators, corticosteroids, antihistamines, and combination inhalers for asthma and COPD management
- Gastroenterology: proton pump inhibitors, antacids, antidiarrheals, antiemetics, and liver care formulations
- Central nervous system: anticonvulsants, antidepressants, anxiolytics, and pain management medicines
- Pediatrics: age-appropriate suspensions, dry syrups, chewable tablets, and drop formulations for paediatric facilities and retail pharmacies
- Women’s health: hormonal therapies, prenatal vitamins, iron and folate supplements, and gynaecological care products
These categories represent consistent volume for distributors supplying retail pharmacy networks and hospital procurement systems, and they form the backbone of a reliable, repeat-order relationship with Afif Overseas.
Injectables and Parenteral Products
The injectable segment is one of the highest-growth areas in Indian pharma exports. Injectables recorded the fastest CAGR of any dosage form category in India in 2025, driven by the scaling of biologics and the growing importance of hospital-administered medicines.
Our injectable range covers IV fluids, small-volume parenterals, lyophilised vials, and ampoules across multiple therapeutic areas. All parenteral products in our portfolio come from dedicated sterile manufacturing facilities operating under strict WHO-GMP conditions, with full batch documentation and cold-chain capability where required.
Active Pharmaceutical Ingredients for Local Manufacturers
For countries investing in building or expanding local pharmaceutical manufacturing capacity, API supply is a strategic priority. India is the third largest API producer globally by volume and contributes approximately 57 percent of APIs on the WHO prequalified list.
Afif Overseas supplies APIs and bulk drugs to local manufacturers looking for reliable, purity-compliant raw material sources. Our API portfolio spans major pharmacopoeial standards including BP, USP, and IP, with full analytical documentation to support your manufacturing quality systems.
One Partner, Complete Coverage
The practical advantage of working with Afif Overseas is that you are not piecing together a supply chain from multiple fragmented sources. You are working with one experienced exporter who knows your market, understands your documentation requirements, and can source across the full spectrum of your product needs from a certified, audited manufacturing network in Ahmedabad and across Gujarat.
We handle the supplier relationships, quality verification, documentation preparation, and logistics coordination. You focus on your market. That division of responsibility is what makes us a genuine partner rather than just another supplier on a list.
Tell Us What Your Market Needs
The best way to understand how our product range fits your specific requirements is to have a direct conversation. Whether you are looking to fulfil a government tender, build a retail distribution portfolio, or source specific therapeutic categories for a hospital network, we are ready to review your product list and come back with a proposal.
Contact Afif Overseas Pvt. Ltd. today
Phone: +91 99790 15551 | Email: info@afifoverseas.com | Website: www.afifoverseas.com
